

6th World Congress and Expo on
Breast Pathology and Cancer Diagnosis

&

20th International Conference on
Medicinal Chemistry and Rational Drugs

July 25-26, 2018 | Vancouver, Canada

Trends in the development of novel approaches to cure benign prostatic hyperplasia: Hormones to
. 5 H H G X F D W H V L Q K L E L W R U V

Neelima Dhingra
University Institute of Pharmaceutical Sciences, India

Benign prostatic hyperplasia (BPH) a common condition of aging men is characterized by nonmalignant enlargement of the prostate gland, and clinically manifested as lower urinary tract symptoms (LUTS). Past experience reveals that with the advent of profound knowledge of the pathogenesis, the natural history, and risk of the progression and new generation of experiments powered by technological breakthroughs, the concept of management has undergone many changes with time. The specific approach used to treat benign prostatic hyperplasia depends upon number of factors like age, prostate size, weight, and race.

wy mvu6.9 (cn)47 1 5v (f m)3oach usey m96 (s li)-8e04.9 (ra)1(t)6 (rac)-7 (t ,)JTJ 0.b 0kivs (Loe[(w)87cy mvu6.95 ()87 (ysi)

Notes: